Europe Cyclodextrins in Pharma Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Aug 2020
  • Europe
  • 350 Pages
  • No of Tables: 235
  • No of Figures: 49

Europe Cyclodextrins in Pharma Market, By Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin, 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins, Others), Nature (Hydrophilic, Hydrophobic), Form (Solid, Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability, Others), Therapeutics Area (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC), Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (Germany, France, Italy, U.K, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe) – Industry Trends & Forecast to 2027       

Europe Cyclodextrins in Pharma MarketMarket Analysis and Insights  : Europe Cyclodextrins in Pharma Market

Cyclodextrins in Pharma Market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 3.7% in the forecast period of 2020 to 2027 and is expected to reach USD 40,309.13 thousand by 2027. The use of cyclodextrin in drug delivery for improvement of drug stability, bioavailability of insoluble drug and rising prevalence of chronic diseases are the major drivers which propelled the demand of the market in the forecast period.

Cyclodextrins are a family of complex cyclic sugars which consists complex macrocyclic ring of glucose sub-units that are held together by alpha-1,4 glycosidic bonds. The enzymatic decomposition of a starch between simple molecules leads to the formation of cyclodextrin. The wider use of cyclodextrin can be observed in as solvent additives drug delivery, pharmaceutical and chemical industries. Among major uses, cyclodextrin utilized in encapsulation of hydrophobic drug molecules into biological system also helps to improve water solubility, stability and bioavailability of drugs.

Cyclodextrins demand has increased as compared to the precise year with its more use in pharmaceutical industry for drug formulations as additives. The significant use of cyclodextrins in renal diseases and growing healthcare expenditure also creates high demand of cyclodextrins in pharma market. In addition, the demand of cyclodextrins in COVID-19 treatment is likely to be seen in antiviral drug formulation based on research, thus leading to high demand of cyclodextrins. However, stringent rules and regulations along with barriers of conducting diagnostics test is expected to slow down the growth of the cyclodextrins in pharma market in the forecast period.

The cyclodextrins in pharma market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the cyclodextrins in pharma market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

Europe Cyclodextrins in Pharma MarketEurope Cyclodextrins in Pharma Market Scope and Market Size

Cyclodextrins in pharma market is segmented on the basis of type, structure, nature, form, application, therapeutic areas and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

  • On the basis of type, the cyclodextrins in pharma market is segmented into Β cyclodextrin, 2-hydroxypropyl-Β-cyclodextrin, Α cyclodextrin, γ-cyclodextrin, randomly methylated Β-cyclodextrin, sulfobutylether Β-cyclodextrin, and 2-hydroxypropyl-Γ-cyclodextrin. In 2020, B cyclodextrin segment has a large share of cyclodextrins in pharma market because these compounds are widely used in the pharmaceutical field due to their ability to improve drug solubility and stability by forming solid complexes.
  • On the basis of structure, the cyclodextrins in pharma market is segmented into cyclodextrin conjugates, mucoadhesive drug carriers, cyclodextrin associates, amphiphilic cyclodextrins, others. In 2020, cyclodextrin conjugation plays a major role in cyclodextrin in the pharmaceutical market as this structure increases the likelihood of interaction between the cyclodextrin well and the pharmacist. Depending on the reaction and the bonding group, it is possible to form soluble or insoluble polymers.
  • On the basis of nature, the cyclodextrins in pharma market is segmented into hydrophilic, and hydrophobic. In 2020, the hydrophilic segment holds majority of share in cyclodextrins in pharma market due to hydrolysis to provide the water solubility of cyclodextrins (or their complexes).
  • On the basis of form, the cyclodextrins in pharma market is segmented into solid, and liquid. In 2020, solid forms of a large proportion of cyclodextrins in the pharmaceutical market where they are obtained in powder form. Furthermore, solid form is preferred over other forms for some pharmaceutical uses.
  • On the basis of application, the cyclodextrins in pharma market is segmented into drug solubility and dissolution, drug bioavailability, drug safety, drug stability, others. In 2020, drug solubility and dissolution has a large proportion of cyclodextrins in the pharmaceutical market because these compounds have played a very important role in the formation of drugs that are poorly soluble in water by improving the apparent solubility and / or dissolution of the drug by interlacing insertion or solids distribution, which acts as a hydrophilic vector for drugs that have insufficient molecular probability or as an additive in high-dose tablets.
  • On the basis of therapeutic areas, the cyclodextrins in pharma market is segmented into pain management, cardiovascular diseases, behavioral disorder, cancer therapy, rheumatoid arthritis, epilepsy, niemann pick disease type C (NPC), and others. In 2020, Pain management holds major share in the cyclodextrins in pharma market due to Hydroxypropyl-β-cyclodextrin (HPβCD) –diclofenac is a new combination of diclofenac NSAIDs in which the diclofenac molecule is dissolved by HPβCD. This allows diclofenac to be administered as a minimum intravenous (IV) volume.
  • On the basis of distribution channel, the cyclodextrins in pharma market is segmented into direct tender, retail sales, and others. In 2020, direct share dominates countries in the market as it is the main supply of pharmaceutical companies. In addition, pharmaceutical companies need high quality raw materials and do not want to take risks. Buying raw materials through direct channels is very convenient for healthcare professionals as it is purchased wholesale under a service agreement.

Europe Cyclodextrins in Pharma Market Country Level Analysis

The cyclodextrins in pharma market is analyzed and market size information is provided by country, type, structure, nature, form, application, therapeutic areas and distribution channel as referenced above.

The countries covered in the Europe cyclodextrins in pharma market report are Germany, France, Italy, U.K, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe.      

Germany dominates the Europe cyclodextrins in pharma market due to the large number of companies, R & D capabilities and the growing adoption of cyclodextrin in the pharma industry. The infrastructure of the health service is also being developed with significant assistance from public authorities.    

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. 

Increasing Bio Availability of Poor Water Soluble Drugs and Increases Drug Stability Leads the Demand of Cyclodextrin based Products are boosting the Cyclodextrins in Pharma Market 

Cyclodextrins in pharma market also provides you with detailed market analysis for every country growth in cyclodextrins in pharma industry with cyclodextrins in pharma drugs and diagnostic tools sales, impact of advancement in the cyclodextrin in pharma treatment technology and changes in regulatory scenarios with their support for the cyclodextrins in pharma market. The data is available for historic period 2010 to 2018.    

Competitive Landscape and Cyclodextrins in Pharma Market Share Analysis

Cyclodextrins in pharma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to cyclodextrins in pharma market.  

The major companies which are dealing in the Europe Cyclodextrins in pharma market are Cambrex Corporation, Cayman Chemical, Wellona Pharma, Wacker Chemie AG, Cyclolab, Roquette Frères, Merck KGaA, Midas Pharma GmbH and Ligand Pharmaceuticals Incorporated among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the Cyclodextrins in pharma market.

For instance,

  • In July 2018, Merck KGaA and Innocare launched new drug delivery technologies to improve patient compliance in the pharmaceutical sector. The main purpose behind this technology was a great way to create sustained release formulations for almost any class of biological APIs.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the cyclodextrins in pharma market which also provides the benefit for organization to improve their offering for cyclodextrins products in pharma.

Customization Available: Europe Cyclodextrins in Pharma Market 

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLES

TABLE 1 CURRENT ANTIVIRAL DRUGS TESTED OR IN DEVELOPMENT FOR TREATMENT OF COVID-19 AND PROPOSED CYCLODEXTRINS FOR FORMULATION ENHANCEMENT

TABLE 2 PRICE OF 25G BETA-CYCLODEXTRIN

TABLE 3 PRICE OF 100G BETA-CYCLODEXTRIN

TABLE 4 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2017-2027 (USD THOUSAND)

TABLE 5 GLOBA Β CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 6 EUROPE 2-HYDROXYPROPYL-Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 7 EUROPE Α CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 8 EUROPE Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 9 EUROPE RANDOMLY METHYLATED Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 10 EUROPE SULFOBUTYLETHER Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 11 EUROPE 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 12 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE 2019-2027 (USD THOUSAND)

TABLE 13 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)

TABLE 14 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 15 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)

TABLE 16 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 17 EUROPE CYCLODEXTRINS ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 18 EUROPE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 19 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 20 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 21 EUROPE OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 22 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2019-2027 (USD THOUSAND)

TABLE 23 EUROPE SOLID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 24 EUROPE LIQUID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 25 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2019-2027 (USD THOUSAND)

TABLE 26 EUROPE HYDROPHILIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 27 EUROPE HYDROPHOBIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 28 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2019-2027 (USD THOUSAND)

TABLE 29 EUROPE DRUG SOLUBILITY AND DISSOLUTION IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 30 EUROPE DRUG BIOAVAILABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 31 EUROPE DRUG SAFETY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 32 EUROPE DRUG STABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 33 EUROPE OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 34 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2017-2027 (USD THOUSAND)

TABLE 35 GLOBA PAIN MANAGEMENT IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 36 GLOBA CARDIOVASCULAR DISEASES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 37 GLOBA BEHAVIORAL DISORDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 38 GLOBA CANCER THERAPY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 39 GLOBA RHEUMATOID ARTHRITIS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 40 GLOBA EPILEPSY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 41 GLOBA NIEMANN PICK DISEASE TYPE C (NPC) IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 42 GLOBA OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 43 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)

TABLE 44 EUROPE DIRECT TENDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 45 EUROPE RETAIL SALES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 46 EUROPE OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 47 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 48 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 49 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 50 EUROPE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 51 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 52 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 53 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 54 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 55 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 56 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 57 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 58 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 59 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 60 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 61 GERMANY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 62 GERMANY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 63 GERMANY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 64 GERMANY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 65 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 66 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 67 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 68 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 69 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 70 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 71 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 72 FRANCE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 73 FRANCE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 74 FRANCE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 75 FRANCE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 76 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 77 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 78 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 79 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 80 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 81 U.K CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 82 U.K CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 83 U.K CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 84 U.K CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 85 U.K MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 86 U.K AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 87 U.K CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 88 U.K CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 89 U.K CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 90 U.K CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 91 U.K CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 92 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 93 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 94 ITALY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 95 ITALY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 96 ITALY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 97 ITALY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 98 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 99 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 100 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 101 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 102 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 103 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 104 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 105 NETHERLANDS CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 106 NETHERLANDS CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 107 NETHERLANDS MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 108 NETHERLANDS AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 109 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 110 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 111 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 112 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 113 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 114 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 115 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 116 SPAIN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 117 SPAIN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 118 SPAIN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 119 SPAIN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 120 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 121 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 122 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 123 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 124 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 125 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 126 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 127 RUSSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 128 RUSSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 129 RUSSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 130 RUSSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 131 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 132 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 133 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 134 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 135 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 136 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 137 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 138 SWITZERLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 139 SWITZERLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 140 SWITZERLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 141 SWITZERLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 142 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 143 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 144 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 145 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 146 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 147 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 148 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 149 BELGIUM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 150 BELGIUM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 151 BELGIUM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 152 BELGIUM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 153 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 154 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 155 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 156 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 157 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 158 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 159 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 160 TURKEY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 161 TURKEY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 162 TURKEY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 163 TURKEY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 164 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 165 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 166 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 167 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 168 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 169 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 170 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 171 AUSTRIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 172 AUSTRIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 173 AUSTRIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 174 AUSTRIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 175 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 176 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 177 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 178 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 179 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 180 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 181 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 182 NORWAY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 183 NORWAY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 184 NORWAY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 185 NORWAY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 186 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 187 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 188 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 189 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 190 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 191 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 192 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 193 HUNGARY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 194 HUNGARY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 195 HUNGARY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 196 HUNGARY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 197 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 198 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 199 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 200 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 201 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 202 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 203 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 204 LITHUANIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 205 LITHUANIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 206 LITHUANIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 207 LITHUANIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 208 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 209 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 210 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 211 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 212 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 213 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 214 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 215 IRELAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 216 IRELAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 217 IRELAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 218 IRELAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 219 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 220 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 221 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 222 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 223 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 224 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 225 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 226 POLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 227 POLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 228 POLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 229 POLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 230 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 231 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 232 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 233 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 234 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 235 REST OF EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions